NKGEN BIOTECH
NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. Leveraging proprietary cell expansion and activation technologies along with cutting-edge cell manufacturing expertise, NKGen Biotech has the ability to infinitely expand natural killer cells while significantly enhancing cytotoxicity.
NKGEN BIOTECH
Industry:
Biotechnology Life Science
Founded:
2017-01-01
Address:
Santa Ana, California, United States
Country:
United States
Website Url:
http://www.nkgenbiotech.com
Total Employee:
51+
Status:
Active
Contact:
949.396.6830
Total Funding:
11 M USD
Technology used in webpage:
SPF Nginx Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Amazon Route 53 Amazon CloudFront Browse Happy Google No Translate
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Gaingels
Gaingels investment in Seed Round - NKGen Biotech
Official Site Inspections
http://www.nkgenbiotech.com Semrush global rank: 3.78 M Semrush visits lastest month: 3.54 K
- Host name: chir209.websitehostserver.net
- IP address: 184.154.155.98
- Location: Chicago United States
- Latitude: 41.8777
- Longitude: -87.6376
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60604
More informations about "NKGen Biotech"
NKGen Biotech - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 949.396.6830 NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on the …See details»
NKGen Biotech Company Profile | Management and Employees …
Our first in class autologous product, SNK01, is currently in a Phase I clinical trial in advanced refractory solid tumors and completed a Phase 1/2a combination trial with Keytruda in Stage …See details»
NKGen Biotech - Overview, News & Similar companies - ZoomInfo
May 16, 2024 NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting SANTA ANA, Calif., April 24, 2024 (GLOBE …See details»
NKGen Biotech, Inc. Information - RocketReach
The mission of NKGen Biotech is to improve patients' lives in a safe and natural way through innovative cell therapy products and to ultimately become the global leader in immune cell …See details»
NKGEN Biotech
NKGen Biotech is harnessing the power of the immune system to fight diseases. Their treatments target natural killer (NK) cells in order to enhance the patient’s immune system for effective …See details»
Maximizing Immune Integrity | NKGen Biotech
NKGen Biotech is leveraging the power of a patient's immune system through the development of unique natural killer (NK) cell therapies.See details»
NKGen Biotech, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
May 8, 2025 NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com. Forward-Looking Statements Statements contained in …See details»
NKGen Biotech Inc. - Cruelty Free Investing
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell …See details»
NKGen Biotech Announces International and U.S. Expansion of
6 hours ago Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). ... For more information, please visit …See details»
NKGen Biotech - Funding, Financials, Valuation & Investors
Apr 11, 2021 NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.See details»
Our Technology | NKGen Biotech
NKGen Biotech’s U.S. headquarters is a state-of-the-art cGMP cell therapy manufacturing facility. At 25,000 square feet, it is home to our growing U.S. team including our CAP/CLIA certified …See details»
Investor Relations | NKGen Biotech
May 8, 2025 Our Mission and Vision. NKGen Biotech’s mission is to improve patient outcomes in neurodegenerative disease and cancer by developing safe and effective cellular therapies …See details»
Our History | NKGen Biotech
NKGen announces troculeucel as the INN name assigned to SNK01 by the World Health Organization (WHO). First patient dosed in the Phase I/IIa trial of troculeucel in moderate …See details»
NKGen Biotech Announces International and U.S. Expansion of …
18 hours ago SANTA ANA, Calif., June 23, 2025 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and …See details»
NKGen Biotech Activates New Clinical Trial Sites in Canada and
6 hours ago [email protected]. External Contacts: Kevin Gardner Managing Director LifeSci Advisors, LLC [email protected]. This article was originally published on …See details»
NKGen Biotech, Inc. (NKGen Biotech, Inc.) - 药物管线_专利_临床试 …
NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com. Forward-Looking Statements Statements contained in this press …See details»
NKGen Biotech Announces International and U.S. Expansion of …
6 hours ago NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is …See details»
NKGen Biotech to Present Troculeucel Clinical and Biomarker
May 7, 2025 Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). ... For more information, please visit …See details»
NKGen Biotech To Present on the Use of Troculeucel for
Apr 14, 2025 Troculeucel is the International Nonproprietary Name (“INN”) for SNK01 assigned by the World Health Organization (“WHO”). ... For more information, please visit …See details»
NKGen Biotech to Present Phase 1 Results on Troculeucel NK
Mar 25, 2025 Troculeucel, now recognized by the World Health Organization with an official nonproprietary name, is part of NKGen's efforts to develop novel NK cell therapies for …See details»